Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(33%)

Results Posted

100%(1 trials)

Phase Distribution

Ph phase_1

33%

Ph not_applicable

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 1Safety & dosage

1(50.0%)

N/ANon-phased studies

1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Other(1)

Detailed Status

Completed1

Recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 11 (50.0%)

N/A1 (50.0%)

Trials by Status

completed133%

recruiting133%

unknown133%

Recent Activity

1 active trials

Showing 3 of 3

recruitingnot_applicable

Single Fraction Preoperative Radiotherapy for Early Stage Breast Cancer

NCT04679454

unknownphase_1

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

NCT05429905

completed

Trends in Modern Phase 1 Oncology Trials

NCT03676270

Clinical Trials (3)

Showing 3 of 3 trials

NCT04679454Not Applicable

Single Fraction Preoperative Radiotherapy for Early Stage Breast Cancer

Recruiting

NCT05429905Phase 1

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Unknown

NCT03676270

Trends in Modern Phase 1 Oncology Trials

Completed

All 3 trials loaded

Drug Details

Intervention Type: RADIATION
Total Trials: 3